Patents by Inventor James S. Huston

James S. Huston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190225688
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 25, 2019
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20190211079
    Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Inventors: Jonathan H. Davis, James S. Huston
  • Patent number: 10239944
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20170145078
    Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 25, 2017
    Inventors: Jonathan H. Davis, James S. Huston
  • Publication number: 20170066826
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 9, 2017
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. BOSQUES, James S. HUSTON, Jonathan C. LANSING, Leona E. LING, James MEADOR, III, Daniel ORTIZ, Laura RUTITZKY, Birgit C. SCHULTES
  • Patent number: 9505848
    Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 29, 2016
    Assignee: Merck Patent GmbH
    Inventors: Jonathan H. Davis, James S. Huston
  • Publication number: 20160229913
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 11, 2016
    Inventors: Carlos J. BOSQUES, James S. HUSTON, Jonathan C. LANSING, Leona E. LING, James MEADOR, III, Daniel ORTIZ, Laura RUTITZKY, Birgit C. SCHULTES
  • Publication number: 20160031985
    Abstract: The disclosure relates to charge-engineered antibodies and penetration-enhanced targeted proteins and their uses for therapeutic treatment or therapeutics delivery.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Katherine S. Bowdish, James S. Huston, Erik M. Vogan, Heather Cooke, John Ross, Kai Lin
  • Publication number: 20150104865
    Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Jonathan H. Davis, James S. Huston
  • Publication number: 20150030593
    Abstract: The disclosure relates to penetration-enhanced targeted proteins and their uses for therapeutics delivery.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 29, 2015
    Applicant: PERMEON BIOLOGICS, INC.
    Inventors: Katherine S. Bowdish, James S. Huston, Erik M. Vogan
  • Patent number: 8871912
    Abstract: The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: October 28, 2014
    Assignee: Merck Patent GmbH
    Inventors: Jonathan H. Davis, James S. Huston
  • Publication number: 20070289185
    Abstract: A quilt rack or support which is used in combination with a quilt display or other related fabrics or textiles. The support includes upper, rear and side walls fabricated of wood. Each of the side walls includes an interior slotted area. The slotted areas are curved and sized so as to receive the end portions of elongated support rods. The elongated support rods include flutted portions. In the method of use, a quilt is draped over a top elongated support rod and retained in a display position via cooperation between the top elongated support rod and a lower elongated support rod.
    Type: Application
    Filed: June 5, 2006
    Publication date: December 20, 2007
    Inventor: James S. Huston
  • Patent number: 7105638
    Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.
    Type: Grant
    Filed: February 4, 1993
    Date of Patent: September 12, 2006
    Assignee: Micromet AG
    Inventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
  • Publication number: 20020168375
    Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
    Type: Application
    Filed: June 21, 2001
    Publication date: November 14, 2002
    Applicant: Chiron Corporation
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Publication number: 20020132990
    Abstract: There is disclosed a gene-delivery compound comprising: (A) a single-chain binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; and (B) a nucleic acid-binding moiety which is coupled to the polypeptide via the cysteinyl residue. There is disclosed also a gene-delivery compound comprising: (A) a single-chain, binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; (B) a lipid-associating moiety which is coupled to the polypeptide via the cysteinyl residue. Additionally disclosed are compositions comprising the above-mentioned compounds and a nucleic acid.
    Type: Application
    Filed: June 25, 2001
    Publication date: September 19, 2002
    Inventors: James S. Huston, Pierre Wils, Quan Zhu, Oliver Laurent, Wayne A. Marasco, Daniel Scherman
  • Patent number: 6207804
    Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic VH and VL dimers, 2) VH-VL or VL-VH single chains wherein the VH and VL are attached by a polypeptide linker, or 3) individual VH or VL domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: March 27, 2001
    Assignee: Curis, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5888773
    Abstract: The invention relates to a method of producing single-chain Fv molecules in eukaryotic cells, and to secretable sFv proteins having at least one non-naturally occurring glycosylation site. The single-chain Fv molecules produced by this method are biologically active and capable of being secreted from eukaryotic cells into the cell culture medium.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: March 30, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Carolina R. Jost, David M. Segal, James S. Huston
  • Patent number: 5877305
    Abstract: Disclosed is DNA encoding a single-chain Fv (sFv) polypeptide defining a binding site which exhibits the immunological binding properties of an immunoglobulin molecule which binds c-erbB-2 or a c-erbB-2-related tumor antigen, the sFv includes at least two polypeptide domains connected by a polypeptide linker spanning the distance between the C-terminus of one domain and the N-terminus of the other, the amino acid sequence of each of the polypeptide domains includes a set of complementarity determining regions (CDRs) interposed between a set of framework regions (FRs), the CDRs conferring immunological binding to the c-erbB-2 or c-erbB-2-related tumor antigen.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: March 2, 1999
    Assignees: Chiron Corporation, Creative BioMoelcules, Inc.
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
  • Patent number: 5861156
    Abstract: Methods of delivering agents to target cells including methods of immunotherapy, are disclosed in which monospecific binding proteins are administered to a host and bind to target cells followed by administration of multivalent antibodies to direct the agents to the target cells.
    Type: Grant
    Filed: January 8, 1993
    Date of Patent: January 19, 1999
    Assignees: Creative BioMolecules, The United States of America as represented by the Department of Health and Human Services
    Inventors: Andrew J. T. George, David M. Segal, James S. Huston
  • Patent number: 5837846
    Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 17, 1998
    Assignees: Creative BioMolecules, Inc., Chiron Corporation
    Inventors: James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann